Table 2.
Univariate analysis of clinical parameters affecting the prognosis of IIIA-N2 NSCLC patients.
| Parameters | All patients (n = 3,445) | No. of patients with <6 positive lymph nodes (n = 2,735) | No. of patients with≥ 6 positive lymph nodes (n = 710) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| PORT | |||||||||
| No | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Yes | 0.793 | 0.715–0.881 | <0.001 | 0.836 | 0.741–0.943 | 0.004 | 0.623 | 0.506–0.766 | <0.001 |
| Age at diagnosis | |||||||||
| <60 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| ≥60 | 1.497 | 1.316–1.702 | <0.001 | 1.535 | 1.319–1.786 | <0.001 | 1.492 | 1.169–1.903 | <0.001 |
| Gender | |||||||||
| Male | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Female | 0.671 | 0.605–0.745 | <0.001 | 0.641 | 0.568–0.723 | <0.001 | 0.791 | 0.644–0.972 | 0.026 |
| Race | |||||||||
| Black | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| White | 1.180 | 0.983–1.416 | 0.076 | 1.215 | 0.979–1.507 | 0.077 | 1.137 | 0.804–1.607 | 0.467 |
| Others | 0.902 | 0.649–1.172 | 0.438 | 0.846 | 0.618–1.158 | 0.296 | 1.067 | 0.663–1.718 | 0.789 |
| Year of diagnosis | |||||||||
| 2010 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| 2011 | 1.031 | 0.892–1.191 | 0.682 | 1.085 | 0.916–1.283 | 0.345 | 0.898 | 0.676–1.192 | 0.456 |
| 2012 | 0.994 | 0.853–1.158 | 0.939 | 1.056 | 0.884–1.262 | 0.545 | 0.848 | 0.629–1.145 | 0.282 |
| 2013 | 0.928 | 0.782–1.102 | 0.397 | 0.985 | 0.808–1.200 | 0.878 | 0.847 | 0.598–1.199 | 0.348 |
| 2014 | 0.849 | 0.691–1.044 | 0.121 | 0.862 | 0.075–1.100 | 0.232 | 0.828 | 0.561–1.220 | 0.339 |
| 2015 | 0.800 | 0.565–1.133 | 0.208 | 0.801 | 0.527–1.217 | 0.298 | 0.770 | 0.412–1.439 | 0.413 |
| Primary tumor site | |||||||||
| Main bronchus | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Upper lobe | 0.833 | 0.491–1.412 | 0.479 | 0.930 | 0.463–1.869 | 0.839 | 0.840 | 0.372–1.893 | 0.673 |
| Middle lobe | 0.837 | 0.471–1.488 | 0.544 | 0.950 | 0.450–2.007 | 0.894 | 0.737 | 0.294–1.846 | 0.515 |
| Lower lobe | 1.039 | 0.611–1.767 | 0.887 | 1.168 | 0.580–2.353 | 0.663 | 0.973 | 0.430–2.204 | 0.948 |
| Overlapping lesion | 1.259 | 0.679–2.334 | 0.465 | 1.218 | 0.547–2.711 | 0.630 | 1.947 | 0.729–5.196 | 0.183 |
| Unknown | 0.933 | 0.414–2.100 | 0.867 | 1.642 | 0.634–4.257 | 0.307 | 0.169 | 0.020–1.407 | 0.100 |
| Pathology | |||||||||
| Adenocarcinoma | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Squamous cell | 1.336 | 1.184–1.507 | <0.001 | 1.419 | 1.238–1.625 | <0.001 | 1.227 | 0.943–1.597 | 0.127 |
| Others | 1.367 | 1.106–1.691 | 0.004 | 1.474 | 1.165–1.865 | 0.001 | 1.177 | 0.711–1.949 | 0.526 |
| Pathological grade | |||||||||
| I | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| II | 0.978 | 0.766–1.247 | 0.855 | 1.023 | 0.774–1.352 | 0.873 | 0.751 | 0.453–1.244 | 0.266 |
| III | 1.247 | 0.980–1.587 | 0.073 | 1.266 | 0.961–1.668 | 0.093 | 1.045 | 0.636–1.719 | 0.861 |
| IV | 1.513 | 0.954–2.399 | 0.078 | 1.664 | 0.979–2.831 | 0.060 | 0.936 | 0.369–2.377 | 0.889 |
| Unknown | 0.945 | 0.694–1.286 | 0.718 | 0.878 | 0.614–1.255 | 0.474 | 1.213 | 0.655–2.247 | 0.539 |
| T | |||||||||
| T1 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| T2 | 1.220 | 1.073–1.386 | 0.002 | 1.220 | 1.055–1.411 | 0.007 | 1.092 | 0.835–1.429 | 0.519 |
| T3 | 1.640 | 1.412–1.905 | <0.001 | 1.640 | 1.381–1.949 | <0.001 | 1.432 | 1.056–1.942 | 0.021 |
| POCT | |||||||||
| No | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | ||||||
| Yes | 0.558 | 0.499–0.624 | <0.001 | 0.561 | 0.494–0.638 | <0.001 | 0.503 | 0.401–0.631 | <0.001 |
| No. of positive lymph nodes | |||||||||
| <6 | 1.00 (Ref) | —— | —— | ||||||
| ≥6 | 1.556 | 1.382–1.752 | <0.001 | —— | —— | —— | —— | —— | —— |
Pathological grade I, well differentiated; II, moderately differentiated; III, poorly differentiated; IV, undifferentiated, anaplastic.
HR, hazard ratio; Ref, reference; PORT, postoperative radiotherapy; POCT, postoperative chemotherapy; NSCLC, non-small cell lung cancer.